Lakeland Regional Cancer Center (LRCC) is proud to have been initiated as the only enrolling site in the eastern United States for a metastatic melanoma clinical trial. LRCC is now in the process of screening patients.
The trial, which is developed by OncoSec Medical Incorporated, is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle.
At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
“Data from the Phase I study was very impressive, which demonstrated that the therapy was not only safe but also provided durable therapeutic benefit,” said Manuel Molina, MD, Surgical Oncologist and LRCC principal investigator on this trial. “Advancing into a Phase II study is encouraging and is important for validation of results seen in the Phase I study. We look forward to participating in this trial.”
“Lakeland Regional Cancer Center is a state-of-the-art clinical site and represents an important center of excellence that will add value to enrollment targets and expertise by participating in the study,” said Punit Dhillon, OncoSec President and CEO.
Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the US are diagnosed in a year, resulting in approximately 10,000 deaths. Melanoma originates in melanocytes, the cells which produce the pigment melanin that colors our skin, hair, and eyes. The majority of melanomas are black or brown, but often they can also be skin-colored, pink, red, purple, blue or white. Currently, there remains few treatment options for patients with late stage metastatic disease that can extend survival for the broad population.
For more information on this trial or to find out if you are a candidate, please call (863) 904-1900. To learn more about LRCC and its clinical trials program, please visit www.lrmc.com/cancer-center.